title: Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
authors.forename: Sondes
authors.initials: S
authors.lastname: Hadiji Mseddi
authors.forename: Faten
authors.initials: F
authors.lastname: Kallel
authors.forename: Olfa
authors.initials: O
authors.lastname: Kassar
authors.forename: Moez
authors.initials: M
authors.lastname: Elloumi
authors.forename: Ines
authors.initials: I
authors.lastname: Jedidi
authors.forename: Halima
authors.initials: H
authors.lastname: Sennana
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D020732:Cytogenetic Analysis; D006403:Hematologic Tests; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics*; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide